<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147002</url>
  </required_header>
  <id_info>
    <org_study_id>KB305/2012</org_study_id>
    <secondary_id>BS209</secondary_id>
    <nct_id>NCT02147002</nct_id>
  </id_info>
  <brief_title>Omega-3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3</brief_title>
  <acronym>Omega-3 acids</acronym>
  <official_title>Omega 3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The National Register of Nephrology in 2007 shows, similarly to the European data, a problem&#xD;
      of a high mortality rate among Polish dialysis patients.&#xD;
&#xD;
      The main reason of death among chronically dialysis patients are cardio - vascular system&#xD;
      diseases. According to &quot;The Report on the Condition of Renal Replacement Therapy in Poland in&#xD;
      2007&quot;, these diseases are the cause of 53% deaths in Poland. The patients with chronic kidney&#xD;
      disease (PChN) are particularly at risk of cardio - vascular complications. These&#xD;
      complications occur on average 30 times more often than in the whole population, and among&#xD;
      young dialysis people, these complications occur 300 times more often. In the development of&#xD;
      cardio - vascular complications polyunsaturated Omega-3 acids (especially eicosapentaenoic&#xD;
      acid - EPA and docosahexaenoic acid - DHA) take a special position. The reaction of&#xD;
      polyunsaturated Omega-3 acids on the cardiovascular system results from the enrichment of&#xD;
      phospholipids of cell membranes within EPA and DHA. It should be noted that their impact is&#xD;
      dependent on the type of acid and on the dose. Docosahexaenoic acid reacts with lipids and&#xD;
      lipoproteins, blood pressure, heart rate, amount of glucose, and eicosapentaenoic acid is&#xD;
      responsible for antiplatelet effect.&#xD;
&#xD;
      This project is aiming at defining and elaborating on the connection between Omega-3 acids,&#xD;
      and cardiovascular complications, their influence on the functioning of the cardiovascular&#xD;
      system, and moreover, a better understanding of the effects of therapeutic and&#xD;
      pharmacological therapies in patients at different stages of chronic kidney disease. Carrying&#xD;
      out this project will be a good start to shape an international project in this area.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The survey will cover 90 patients from chronic kidney disease at different stages of the&#xD;
      disease(I-III) and 30 healthy subjects as a comparison group.&#xD;
&#xD;
      At the beginning and at the end of the observation period, besides the clinical test, some&#xD;
      other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory&#xD;
      blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid&#xD;
      profile, uric acid, C reactive protein (CRP), blood urea nitrogen (BUN), creatinine,&#xD;
      morphology, calcium (Ca),phosphorus (P), Ca x P, ionogram, xanthine oxidase, monocyte&#xD;
      chemoattractant protein (MPC1),Omega-3 acids, resolvin and protectins - the metabolites of&#xD;
      Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid. The patients&#xD;
      will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule&#xD;
      = 1000 mg) for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular complications</measure>
    <time_frame>6 months</time_frame>
    <description>Primary measurement before the supplementation and the second measurement after 6 months of supplementation with omega-3 acid.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiovascular Complications</condition>
  <arm_group>
    <arm_group_label>omega 3 acids 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 acids 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 acids 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 acids 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gold omega 3</intervention_name>
    <description>At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.</description>
    <arm_group_label>omega 3 acids 1</arm_group_label>
    <arm_group_label>omega 3 acids 2</arm_group_label>
    <arm_group_label>omega 3 acids 3</arm_group_label>
    <arm_group_label>omega 3 acids 4</arm_group_label>
    <other_name>omega 3 acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - chronic kidney disease (CKD) stage 1-3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  without diabetes&#xD;
&#xD;
          -  without Immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Manitius, prof.</last_name>
    <role>Study Director</role>
    <affiliation>Collegium Medicum in Bydgoszcz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnieszka Pluta, dr</last_name>
    <phone>693716980</phone>
    <phone_ext>0048</phone_ext>
    <email>agnieszkapluta@poczta.onet.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>1Katedra i Klinika Nefrologii, Nadciśnienia Tętniczego i Chorób Wewnętrznych, Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Pluta, dr</last_name>
      <phone>693716980</phone>
      <phone_ext>0048</phone_ext>
      <email>agnieszkapluta@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Paweł Stróżecki, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Manitius</investigator_full_name>
    <investigator_title>prof. dr hab. n.med.</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Cardiovascular Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

